Liquid Biopsy Market Forecasts to 2030 – Global Analysis By Product & Services (Kits & Reagents, Platforms & Instruments and Services), By Type of Sample (Blood, Saliva, Urine and Other Types of Samples), Technology (Multi-gene Parallel Analysis using NGS

Liquid Biopsy Market Forecasts to 2030 – Global Analysis By Product & Services (Kits & Reagents, Platforms & Instruments and Services), By Type of Sample (Blood, Saliva, Urine and Other Types of Samples), Technology (Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays), Circulating Biomarker, Cancer, Clinical Application, End User and By Geography

According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $5.1 billion in 2023 and is expected to reach $18.8 billion by 2030 growing at a CAGR of 20.3% during the forecast period. Liquid biopsy is a non-invasive medical test that detects biomarkers, such as circulating tumor DNA (ctDNA), RNA, and proteins, in bodily fluids like blood or urine. It provides insights into a patient's health, particularly in cancer diagnostics, by identifying genetic mutations or alterations associated with the disease. Liquid biopsy offers a less invasive method to monitor and analyze molecular changes, aiding in early detection, treatment response assessment, and personalized medicine. This innovative approach revolutionizes cancer diagnostics and monitoring, offering a dynamic and real-time perspective on an individual's health status.

According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe.

Market Dynamics:

Driver:

Increasing prevalence of cancer globally

The escalating global prevalence of cancer serves as a significant driver for the liquid biopsy market. As cancer incidence rises worldwide, there is a growing need for effective and non-invasive diagnostic tools. Liquid biopsies, offering a minimally invasive approach to detecting and monitoring cancers, meet this demand. They enable early detection, treatment customization, and real-time monitoring of therapeutic responses. Moreover, the increasing recognition of liquid biopsies as valuable tools in the fight against cancer positions them as a crucial component in addressing the rising burden of this disease on a global scale.

Restraint:

Sensitivity and specificity challenges

The variable performance of these tests in terms of accurately detecting and ruling out specific conditions raises concerns about their reliability. Achieving high sensitivity is crucial for clinical utility. Inconsistent results may lead to false positives or negatives, impacting the overall accuracy of liquid biopsy and thereby hindering overall market growth.

Opportunity:

Government investments on healthcare infrastructure

Increased funding enhances research and development, aiding technological advancements and innovation in liquid biopsy technologies. Improved infrastructure fosters better accessibility to diagnostic services, promoting the adoption of liquid biopsy for early cancer detection. Government support can also facilitate the integration of liquid biopsy into mainstream healthcare systems, ensuring widespread availability. This aligns with public health initiatives, creating a conducive environment for market growth.

Threat:

Stringent regulatory requirements and competition with traditional biopsy methods

Stringent regulatory requirements pose a threat to the liquid biopsy market by potentially slowing down product approvals and market entry. Meeting these requirements demands substantial resources and time. Additionally, the market faces competition from well-established traditional biopsy methods, leading to skepticism and slower adoption. Physicians and healthcare institutions may prefer conventional approaches they are familiar with, hindering the rapid integration of liquid biopsy techniques.

Covid-19 Impact:

The COVID-19 pandemic had a significant effect on the liquid biopsy market. Disruptions in healthcare systems and priorities diverted attention and resources away from non-essential diagnostics, slowing market growth. However, the pandemic underscored the importance of non-invasive and remote diagnostics, fueling interest in liquid biopsy technologies. The need for minimizing patient contact and expediting diagnostic processes accelerated the adoption of liquid biopsies, especially in oncology, demonstrating their potential resilience and adaptability in response to healthcare challenges posed by the pandemic.

The blood segment is expected to be the largest during the forecast period

Over the forecast period, the blood segment is poised to dominate the liquid biopsy market, securing the largest market share. This dominance is attributed to the escalating demand for non-invasive cancer diagnostics and the convenience of obtaining blood samples. Blood-based liquid biopsies, leveraging circulating tumor DNA (ctDNA) and other biomarkers, facilitate early cancer detection and treatment monitoring. Additionally, the segment's growth is further propelled by advancements in high-throughput technologies like next-generation sequencing, which enhance the precision of molecular analysis.

The prostate cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the prostate cancer segment is expected to witness unparalleled growth in the liquid biopsy market. This surge is driven by the pressing need for accurate and minimally invasive diagnostic solutions for prostate cancer, a prevalent and often asymptomatic condition. Liquid biopsy's ability to detect circulating tumor DNA (ctDNA) and other biomarkers from a simple blood draw offers a revolutionary approach to prostate cancer diagnosis and monitoring. Moreover, advancements in liquid biopsy technologies, coupled with a growing emphasis on personalized medicine, position the prostate cancer segment at the forefront of the market's expansion.

Region with largest share:

North America is anticipated to command the largest market share during the forecast period in the liquid biopsy market. This dominance is attributed to factors such as a well-established healthcare infrastructure, increased investment in research and development, and a high prevalence of cancer. Moreover, the region benefits from the early adoption of advanced medical technologies and a strong emphasis on personalized medicine. Additionally, the presence of key market players, coupled with favorable government initiatives, positions North America at the forefront of the liquid biopsy market.

Region with highest CAGR:

The Asia Pacific region is positioned to experience the highest CAGR during the forecast period in the liquid biopsy market. Owing to the rising incidence of cancer, improving healthcare infrastructure, and increasing adoption of advanced diagnostic technologies. The region's large and diverse population, coupled with government initiatives to enhance healthcare services, fosters the demand for non-invasive cancer diagnostics. Additionally, collaborations between international and local companies, along with a growing focus on precision medicine, further drive the expansion of the liquid biopsy market in the Asia Pacific region.

Key players in the market

Some of the key players in Liquid Biopsy Market include ANGLE plc, Biocept Inc., Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Laboratory Corporation of America Holdings, Lucence Health Inc., MDxHealth SA, Myriad Genetics, Inc., Oncimmune, QIAGEN N.V and Thermo Fisher Scientific Inc.

Key Developments:

In November 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation. The test is provided as a service from ANGLE's Onc-ADaPT® GCP-compliant laboratories and is conducted by an expert team with over 10 years' experience in CTC analysis.

In March 2023, ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence short.

Product & Services Covered:
• Kits & Reagents
• Platforms & Instruments
• Services

Type of Samples Covered:
• Blood
• Saliva
• Urine
• Other Types of Samples

Technologies Covered:
• Multi-gene Parallel Analysis using NGS
• Single-gene Analysis using PCR Microarrays

Circulating Biomarkers Covered:
• Cell-free DNA (cfDNA)
• Circulating Tumor Cells
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers

Cancers Covered:
• Breast Cancer
• Colorectal Cancer
• Liver Cancer
• Lung Cancer
• Prostate Cancer
• Other Cancers

Clinical Applications Covered:
• Early Cancer Screening
• Recurrence Monitoring
• Therapy Selection
• Treatment Monitoring
• Other Clinical Applications

End Users Covered:
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutions
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements